Lasa Supergenerics Ltd - 540702 - YEARLY CERTIFICATE FROM PRACTICING COMPANY SECRETARY UNDER REG 40(9) OF SEBI (LODR) REGULATIONS 2015
Pursuant to Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015, We are enclosing herewith the certificate from Shivam Sharma and Associates, Practicing Company Secretaries for the year ended 31st March 2024 Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
Mr.Ravi Shankar kabra, CFO of the company tendered his resignation vide letter dated April 25,2024 due to health reasons and other pre occupations, he will be relieved of his duties effective end of business hours of April 26,2024 Lasa Supergenerics Ltd - 540702 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under regulation 74 (5) SEBI (Depositories and Participants) Regulation''s, 2018 for the quarter and the year ended March 31, 2024 received from Bigshare Services Private Limited, Registrar and Share Transfer Agent of the Company. Lasa Supergenerics Ltd - 540702 - Compliance Under Reg 7(3) SEBI LODR, Regulations 2015 For The Period Ended March 31, 2024
Pursuant to Regulation 7 (3) of SEBI LODR, Regulations 2015, We hereby confirm that all activities in relation to both physical and electronic share transfer facility during period 1st April 2023 to 31st March, 2024 (both days inclusive) are maintained by our Registrar and Share Transfer Agent - BigShare Services Private Limited having permanant SEBI Registration No. INR000001385 Lasa Supergenerics Ltd - 540702 - Closure of Trading Window
This is to Inform you that as per the company code of Conduct for Regulation Monitoring and Reporting of Trading by Insiders in terms of ( Prohibition of Insider Trading) Regulations, 2015, as amended, the Trading window for dealing of Equity Share of the Company has been closed for designated employee and their immediate relatives w.e.f 1st April 2024 to till the 48 hours after the declaration of Audited Financial result (both days inclusive) for the quarter and the year ended March 31, 2024 Lasa Supergenerics Ltd - 540702 - Board Meeting Outcome for Revised Outcome Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Revised outcome of Board Meeting March 08, 2024 Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held on March 08, 2024 which was commenced at 2.00 p.m. and concluded at 3.00 p.m. inter- alia have considered and approved the following: 1. Appointment of Mr. Umesh Pawar (DIN: 10539778) as an Additional Director (Executive Director) of the Company and he shall be designated as Whole-time Director of the Company for a term of 5 (five) years with effect from March 08, 2024, subject to the approval of shareholders at General Meeting of the Company.. We are enclosing herewith the brief details of the aforesaid change as prescribed under SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as Annexure I. Lasa Supergenerics Ltd - 540702 - Board Meeting Outcome for Outcome Of Board Meeting
Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 2.00 p.m. and concluded at 3.00 p.m. inter- alia have considered and approved the following: 1. Appointment of Mr. Umesh Pawar as an Additional Director (Executive Director) of the Company. Further the aforesaid appointment shall be subject to approval of members at the ensuing General Meeting/ Postal Ballot of the Company. Lasa Supergenerics Ltd - 540702 - Board Meeting Outcome for Outcome Of Board Meeting For The Quarter Ended December 31St, 2023
Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 4.00 p.m. and concluded at 6.15 p.m. inter- alia have considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the quarter ended on December 31, 2023. 2. Limited Review Report from Statutory Auditor for the quarter ended on December 31, 2023. Lasa Supergenerics Ltd - 540702 - Board Meeting Intimation for For Unaudited Financial Results Along With Limited Review Report For The Quarter Ended December 31, 2023
Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, February 13, 2024 1. To consider, approve and take on records unaudited financial results of the Company along with the Limited Review Report from the Statutory Auditor for the quarter ended on December 31, 2023. 2. To discuss any other matter with the permission of the Chairperson. Lasa Supergenerics Ltd - 540702 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended December 31, 2023 received from Bigshare Services Private Limited, Registrar and Share Transfer Agent of the Company